Thrilled to be presenting our new business model for accelerating the development of pediatric cancer drugs at the upcoming #ACCELERATEplatform meeting in Brussels. Thanks to @Gilles_Vassal and the steering committee for the invitation. @SIOPEurope https://t.co/qPS0Cxb5zn

Great to hear Mark Kieran at ⁦⁦@bmsnews⁩ discuss the industry perspective on accelerating drug development for pediatric oncology patients. #ACCELERATEplatform #AACR19 ⁦@SIOPEurope⁩ ⁦@ITCC_eu⁩ ⁦@Gilles_Vassal⁩

This is incredibly important work. Congratulations to @SIOPEurope and the #ACCELERATEplatform on advancing this important topic. And also to @US_FDA for their recent draft guidance that similarly advises sponsors to include patients down to age 12 where possible. https://t.co/OmsZGEyLfs

Congratulations to #ACCELERATEplatform for this wonderful achievement. @SIOPEurope @ITCC_eu @Gilles_Vassal (now we just need to get Andy Pearson on Twitter) twitter.com/FDAOncology/status/10994...

What a treat to present the output of WG4 at the #ACCELERATEplatform meeting in #Brussels last week with the amazing Delphine Heenen from @KickCancerBel. https://t.co/gjzAadFEVD

As always, a thought-provoking and productive #ACCELERATEplatform meeting here in #Brussels. Lots to follow-up on, but for now off to Amsterdam for a day at the @rijksmuseum. Many thanks to @SIOPEurope and @Gilles_Vassal for a great 2 days!

Lou Stancato of ⁦@LillyPad⁩ captivating the audience as he presents the #ITCC-P4 platform at the #ACCELERATEplatform meeting. ⁦@SIOPEurope⁩ ⁦@ITCC_eu⁩

Woo hoo! #Snowmaggedon2019 ended. Snow is melting. I-5 is clear. @lyft driver picked me up on time. @SeaTacAirport is open. My @Delta flight looks to be on time. If @thalys_en can get me to Brussels tomorrow then I will be at #ACCELERATEplatform meeting on Thursday! https://t.co/NLwQZJ39D4

If this makes me miss the #ACCELERATEplatform meeting @SIOPEurope I will be very angry. twitter.com/CliffMass/status/1093268...

Very excited to be presenting the output of #ACCELERATEplatform Working Group 4 next month in Brussels with my colleagues Delphine Heenen of @KickCancerBel and @PatriciaBlancIM of @ImagineforMargo. twitter.com/SIOPEurope/status/108842...

N. Gaspar highlights a key opportunity to increase accrual to ped onc Ph1 drug trials: include adults with peds cancers. #ACCELERATEplatform

Congrats to Lou Stancato at Eli Lilly for his strong work on ITCC-P4. We need these peds PDX models! #ACCELERATEplatform @ITCC_eu @LillyPad

Peter Adamson highlights a key issue with declaring an MoA to be "relevant" for peds. Current models are limited. #ACCELERATEplatform

Andy Pearson reviewing EMA class waivers. I believe this will continue to be a major area of debate for a while. #ACCELERATEplatform

Excellent presentation from Martha Donoghue of @US_FDA showing strong commitment to advancing peds onc drug development. #ACCELERATEplatform

Wow. In the past 10 years, only 10 PIPs completed out of 93 accepted. Need to increase ratio of reward:burden. #ACCELERATEplatform

Peter Adamson's suggestion is great. We need a paper on "Top 10 Myths of Pediatric Drug Development" #ACCELERATEplatform

Session 1 action item: we need to start drug development program for "Regulatory Anxiety Syndrome". No PIP, I hope. #accelerateplatform

We need to solve structural issues at acad med ctrs that limit our ability to include adolescent pts on adult Ph1 trials #accelerateplatform

Peter Adamson: "Pediatric oncologists have permeated all of Pharma."

He's right. We're everywhere, trying to do good.
#accelerateplatform

Did I mention that one of the benefits of being st #accelerateplatform here in Brussels is that nobody is talking about trump (so far)?

Keen to see if #accelerateplatform will discuss crunch of multiple pedi ALL studies (CD19 CAR-T cells, blina) and how to prioritize.

Adamson: also noting burden of PIP dev relative to incentives, especially true when there are mult drugs in same class #accelerateplatform

Adamson: highlighting the desire for proof-of-concept before sponsors are willing to start pediatric development work #accelerateplatform

Peter Adamson right to highlight the 6 YEAR delay in starting inotuzumab pediatric trial. "This is a pediatric disease" #accelerateplatform

A key part the dabrafenib PIP was suggestion by PDCO to employ PK modeling to address rare peds melanoma indication. #accelerateplatform

Would love to see mutual recognition between FDA and EMA for PIPs/peds development plans ... #accelerateplatform twitter.com/zacharybrennan/status/83...

Genentech talk on MOA-directed peds development highlights need for coordination and prioritization between sponsors. #ACCELERATEplatform